Fountain Life, MD-Led Platform

Fountain Life is an executive health and longevity medicine company co-founded by physician and entrepreneur Peter Diamandis alongside physician and longevity expert Bill Kapp. The company's founding vision was to deliver the diagnostic capabilities of the world's best academic medical centers — full-body MRI, cardiac CT angiography, whole-genome sequencing, neurocognitive testing, epigenetic aging clocks — in a membership model accessible to high-net-worth individuals and corporations willing to make a serious preventive health investment. The company's flagship offering is its early detection protocol. Where standard preventive medicine relies on population-based screening guidelines — mammograms at 40, colonoscopy at 45, PSA testing with caveats — Fountain Life applies comprehensive imaging and genomic analysis to every member annually, regardless of symptoms or guidelines. The company reports a 3% cancer detection rate and a 3.5% aneurysm detection rate at first scan, meaning roughly 1 in 30 new members discovers a serious previously undetected condition at their first visit. The company frames this not as alarming but as precisely the outcome that justifies the investment: cancers found at Stage 1, when five-year survival rates are typically above 90%, versus Stage 4 diagnoses that occur because conventional screening was not triggered. Fountain Life operates physical centers in Naples and Orlando, Florida, Dallas, Texas, and the New York metropolitan area, with Miami and Houston expansions underway as of 2025. The in-person requirement is non-negotiable for the diagnostic value proposition — full-body MRI and cardiac CT cannot be delivered remotely. Between in-person visits, an AI-powered monitoring platform tracks biomarker trends and flags anomalies, and members have telehealth access to Fountain Life physicians for protocol management, prescription refills, and follow-up questions. The pricing structure — $10,500/year for CORE, $21,500/year for APEX — places Fountain Life squarely in the corporate benefit and ultra-high-net-worth individual market. The company has been increasingly active in selling corporate executive health packages, where the ROI argument is made in terms of protecting key personnel and reducing catastrophic healthcare costs through early intervention. Independent analysis cited by the company suggests a 13:1 return on investment over a decade through early detection savings. For patients who want the deepest available look at their health and have the means to pay for it, Fountain Life represents the current ceiling of consumer-accessible preventive medicine. testing, epigenetic aging clocks — in a membership model accessible to high-net-worth individuals and corporations willing to make a serious preventive health investment. The company's flagship offering is its early detection protocol. Where standard preventive medicine relies on population-based screening guidelines — mammograms at 40, colonoscopy at 45, PSA testing with caveats — Fountain Life applies comprehensive imaging and genomic analysis to every member annually, regardless of symptoms or guidelines. The company reports a 3% cancer detection rate and a 3.5% aneurysm detection rate at first scan, meaning roughly 1 in 30 new members discovers a serious previously undetected condition at their first visit. The company frames this not as alarming but as precisely the outcome that justifies the investment: cancers found at Stage 1, when five-year survival rates are typically above 90%, versus Stage 4 diagnoses that occur because conventional screening was not triggered. Fountain Life operates physical centers in Naples and Orlando, Florida, Dallas, Texas, and the New York metropolitan area, with Miami and Houston expansions underway as of 2025. The in-person requirement is non-negotiable for the diagnostic value proposition — full-body MRI and cardiac CT cannot be delivered remotely. Between in-person visits, an AI-powered monitoring platform tracks biomarker trends and flags anomalies, and members have telehealth access to Fountain Life physicians for protocol management, prescription refills, and follow-up questions. The pricing structure — $10,500/year for CORE, $21,500/year for APEX — places Fountain Life squarely in the corporate benefit and ultra-high-net-worth individual market. The company has been increasingly active in selling corporate executive health packages, where the ROI argument is made in terms of protecting key personnel and reducing catastrophic healthcare costs through early intervention. Independent analysis cited by the company suggests a 13:1 return on investment over a decade through early detection savings. For patients who want the deepest available look at their health and have the means to pay for it, Fountain Life represents the current ceiling of consumer-accessible preventive medicine.